Gedeon Richter Strikes $16.5m Global Tocilizumab Deal
Agreement For Biosimilar To Actemra/RoActemra Reached With Taiwan’s Mycenax
Gedeon Richter has struck a deal worth $16.5m with Taiwan’s Mycenax for global rights to a tocilizumab biosimilar version of Actemra/RoActemra, setting a date for planned launches in the EU, Japan, Canada and Australia.
You may also be interested in...
Roche gave small insight into its expectations around biosimilar competition for its Actemra/RoActemra (tocilizumab) treatment for inflammatory diseases. Extraordinary demand for the biologic led sales to skyrocket by 143% in the third quarter and caused supply constraints for the originator.
Fresenius Kabi has reported positive Phase I data for its MSB11456 proposed tocilizumab biosimilar rival to Actemra/Ro-Actemra, against the backdrop of shortages for the brand which is being used in some regions to treat COVID-19.
Biogen and Bio-Thera Solutions have reported positive results from a Phase III trial for their BAT1806 proposed biosimilar tocilizumab rival to Actemra. The milestone has triggered a $30m payment from Biogen under the pair’s development deal.